SPOTLIGHT: FDA expands antidepressant black box warning

The FDA announces it will expand the black box warnings on antidepressant drugs to "include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during initial treatment." Previously the FDA warned antidepressants could cause suicidal behavior in children. The FDA had debated how to clarify the warning, as antidepressant sales have dropped 13 percent since the black box was added. The "important message going forward is that these drugs have value across the age spectrum, but that patients must be monitored especially early in treatment," noted Thomas Laughren of the FDA's psychiatry products division. Warning | Article (WSJ sub. req.)

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.